Author

Laia Solé-Feu

Observed names: L. Sole-Feu, L. Solé-Feu, Laia Solé‐Feu

Institution: Almirall (Spain)

Observed institutions: Almirall (Spain), Parc Científic de Barcelona

ORCID: 0009-0003-5952-6592

Observed ORCID: 0009-0003-5952-6592

OpenAlex ID: A5093751397

Suzuki coupling reaction for the solid-phase preparation of 5-substituted nicotinic acid derivatives

2004 · Joan-Carles Fernàndez, Laia Solé-Feu, et al. · Tetrahedron Letters · 24

Solid‐Phase N‐Electrophilic Amination of 2‐Aminopyridines: Preparation of 2‐Substituted‐[1,2,4]triazolo[1,5‐a]pyridine Derivatives

2006 · Joan‐Carles Fernàndez, Laia Solé‐Feu, et al. · QSAR & Combinatorial Science · 6

Letter to the Editor Regarding “Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo Adjusted Indirect Treatment Comparison”

2025 · Raj Chovatiya, Lucia Seminario-Vidal, et al. · Dermatology and Therapy · 2

CO90 Matching-Adjusted Indirect Comparison of Efficacy and Safety for Lebrikizumab, Dupilumab, and Tralokinumab in Patients With Moderate-to-Severe Atopic Dermatitis Not Adequately Controlled or Non-eligible for Cyclosporine

2024 · K Ezzedine, G Caillet, et al. · Value in Health · 1

EE705 Cost-Effectiveness Model of Lebrikizumab Compared to Dupilumab in the Treatment of Austrian Patients With Moderate to Severe Atopic Dermatitis

2024 · B Schwarz, L. Sole-Feu, et al. · Value in Health · 1

Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis

2024 · Kim Rand, Juan Manuel Ramos-Goñi, et al. · Dermatology and Therapy · 1

Cost-Effectiveness Analysis of Lebrikizumab versus Dupilumab for Patients with Severe Atopic Dermatitis in Austria

2026 · Bernhard Schwarz, Laia Solé-Feu, et al. · ClinicoEconomics and Outcomes Research

EE211 Cost-Effectiveness Analysis of Lebrikizumab vs. Alternative Biologics in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis in the UK

2025 · Warda Tahir, Vanessa Buchanan, et al. · Value in Health

HTA202 Health Technology Assessment (HTA) and Reimbursement Decisions for the New Anti-IL-13 Monoclonal Antibody Lebrikizumab for Patients With Moderate to Severe Atopic Dermatitis (AD) in Europe

2024 · L. Solé-Feu, B Akmaz, et al. · Value in Health

Response to “Letter to the Editor Regarding ‘Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis’”

2024 · Kim Rand, Juan Manuel Ramos-Goñi, et al. · Dermatology and Therapy

Works count: 10

Citation count: 35

H-index: 2

I10-index: 1